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and indeed, the patients with long-standing UC have a 
high-risk of its associated colorectal cancer （colitic 
cancer）1, 2）. The colitic cancer is believed to arise 
through a chronic inflammation-dysplasia-carcinoma 
sequence, and therefore, the early detection of precan­
cerous dysplasia is very important to improve the 
prognosis of long-standing UC patients. In practice, 
the surveillance of UC patients are performed by the 
repeated endoscopical examinations 3〜5）；however, 
UC-associated neoplasia is frequently difficult to detect 
endoscopically. Moreover, it is difficult to discriminate 
the UC-associated neoplasia from inflammed regener­
ating epithelium even by pathological examination. 
INTRODUCTION
The pathogenesis of ulcerative colitis （UC） is still 
unclear, but dysregulation of immune system appears 
to be involved in its chronic inflammatory process. As 
recent studies have suggested, inflammation plays im­
portant roles in the development of various cancers, 
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SUMMARY
The patients with long-standing ulcerative colitis （UC） have a high-risk of neoplastic lesions in the colon­
ic mucosa. The UC-associated neoplastic lesion is difficult to detect by endoscopic examination or diagnose 
histologically. In the present study, we aimed to clarify whether immunohistochemistry for p53 is useful to 
discriminate the UC-associated neoplasia from inflammed regenerating epithelium. Tissue samples were ob­
tained from colorectomy specimens from 20 patients with long-standing UC （range 6-29 years）. The sur­
face of microstructure of the tissues was observed by stereomicroscopy, and the sections were examined us­
ing immunohistochemistry for p53. All of T2-4 carcinomas were detectable by endoscopic examination before 
surgery, whereas considerable number of dysplasias （52.5％）, Tis carcinomas （33.3％）, and T1 carcinomas 
（60.0％） were undetectable. Fifty-three of 67 UC-associated neoplastic lesions （79.1％） were of flat-type 
macroscopically. The detection rate of flat-type neoplasias （45.3％） was significantly lower than that of pro­
truding ones （100％）. The positivity of p53 overexpression was 0％ in UC-II, 52.5％ in UC-III, and 70.4％ 
in UC-IV, respectively. UC-II lesions had lower positivity of p53 overexpression than UC-III （P＝0.027） or 
-IV lesions （P＝0.003）. Immunohistochemical analysis of p53 protein is useful to discriminate the UC-associ­
ated neoplasia from inflammed regenerating epithelium.
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finized, rehydrated, and then pretreated with 0.3％ 
H2O2 in methanol for 20 min at room temperature to 
quench endogenous peroxidase activity. The sections 
were then placed in 0.01 mol/L citrate buffer （pH 6.0） 
and treated by microwave heating （MI-77, Azumaya, 
Tokyo, Japan；400 W, 95℃） for 10 min to facilitate an­
tigen retrieval. The sections were incubated with 1％ 
bovine serum albumin in phosphate-buffered saline 
（PBS） for 30 min, and then with anti-human p53 anti­
body （NCL-p53-CM1；Novocastra Laboratories, New­
castle, UK；dilution 1：2000） for 1 hour. Thereafter, 
the sections were incubated with biotinylated second­
ary antibody for 15 min, washed with PBS, and treated 
with peroxidase-conjugated streptavidin for 20 min. 
Finally, the sections were incubated in 3,3 ’-diamin­
obenzidine tetrahydrochloride with 0.05％ H2O2 for 3 
min and then counterstained with Carazzi’s hematoxy­
lin. Immunoreactivity was evaluated as positive when 
a focal nuclear accumulation of p53 protein was detect­
ed.
Statistical analysis
Statview 5.0J statistical software （Abacus Concepts 
Inc., Berkeley, CA） was used for all analyses. Chi-
squared analyses were performed to investigate the 
relationship between p53 expression and clinicopatho­
logical features. All values were expressed as the mean
±SEM, and the significance of differences between 
two groups was assessed using Mann-Whitney U-test. 
Differences at P＜0.05 were considered to be signifi­
cant.
RESULTS
Macroscopic appearance and detection rate of ulcerative 
colitis-associated neoplastic lesions
As shown in Table 1, 21 of 40 （52.5％） dysplasias, 5 
of 15 （33.3％） Tis carcinomas, and 3 of 5 （60.0％） T1 
carcinomas were undetectable by endoscopic examina­
tion before surgery, whereas all of T2-4 carcinomas 
were detectable. The advanced lesions in T2-T4 stage 
was significantly detectable than dysplasia or T1 carci­
nomas；however, the detection rates of dysplasia, Tis 
carcinoma, and T1 carcinoma were not different statis­
tically.
When classified UC-associated neoplastic lesions ac­
cording to macroscopic appearance, 53 of 67 （79.1％） 
Therefore, in the present study we aimed to clarify 
whether immunohistochemical detection of p53-over­
expression is useful to discriminate the UC-associated 
neoplasia from inflammed regenerating epithelium.
MATERIALS AND METHODS
Patients
Tissue samples were obtained from colorectomy 
specimens from 20 patients with UC （10 males, 10 fe­
males；mean age 48.4±1.6 years, range 39-64 years；
mean disease duration 17.1±1.1 years, range 6-29 
years） who had undergone total coloctomy for UC-as­
sociated neoplasia. Endoscopic examinations before 
surgery were performed by specialists for endoscopy.
Histological assessment
All specimens from the colectomies were opened lon­
gitudinally, fixed in 10％ formalin solution and stained 
with alcian blue （pH 2.5） and Carazzi’s haematoxylin 
or crystal violet. The surface of microstructure of the 
tissue was observed using stereomicroscopy. The mac­
roscopic appearance of neoplastic lesions was sub-
grouped into protruding and flat-type. After stereomi­
croscopic observation, the whole tissues were sectioned 
at intervals of 5 mm, embedded in paraffin and stained 
with haematoxylin and eosin.
Each specimen was graded as follows：inflammatory 
change （UC-I）；indefinite （UC-II）；neoplastic but 
not carcinoma （UC-III）；carcinoma （UC-IV）. This 
classification was proposed by the Research Commit­
tee of Inflammatory Bowels Disease of the Ministry of 
Health and Welfare of Japan 6）. T grade was evaluated 
according to the International Union Against Cancer 
TNM staging system as follows：Tis, intraepithelial or 
invasion of lamina propria；T1, tumor invades submu­
cosa；T2, tumor invades muscularis propria；T3, tu­
mor invades through muscularis propria into subserosa 
or into non-peritonealized pericoloic or perirectal tis­
sues；T4, tumor directly invades other organs or 
structures and/or perforates visceral peritoneum.
Immunoshitochemistry
Immunohistochemical staining for p53 was per­
formed with a LSAB-2 kit （DAKO, Marseille, France） 
as described previously 7）. In brief, the sections （4-mm-
thick） placed on silane-coated slides were deparaf­
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lesions were of flat-type （Figure 1A and B）. In detail, 
37 of 40 （92.5％） dysplasias, 12 of 15 （80.0％） Tis car­
cinomas, 3 of 5 （60.0％） T1 carcinomas were of flat-
type, whereas 6 of 7 （85.7％） T2-4 carcinomas were 
protruding （Figure 1C and D）. In each T category, the 
detection rate of lesions tended to be high in the pro­
truding-type. Overall, the detection rate of flat-type 
neoplasias （45.3％） was significantly lower than that 
of protruding ones （45.3％ vs 100％；P＝0.0002）.
p53-overexpression in ulcerative colitis and its associat-
ed neoplastic lesions
Seventy-two specimens were included in the immu­
nohistochemical analysis for p53. We observed the 
accumulation of p53 immunoreactivity in the nuclei of 
tumor cells （Figure 2）. The positivity of p53 overex­
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Table 1　 Relationship between detection and macroscopic appearance of 
UC-associated neoplastic lesions
T grade P value protruding flat ＊P value
Dysplasia （n＝40） 
　　detectable 19 3 16
0.058
　　undetectable 21 0 21
Tis （n＝15） 
　　detectable 10
0.205a
3 7
0.171
　　undetectable 5 0 5
T1 （n＝5） 
　　detectable 2 0.751a
0.292b
2 0
＜0.05
　　undetectable 3 0 3
Advanced （n＝7） 
　　detectable 7 ＜0.05a
0.082b
＜0.05c
6 1
ND
　　undetectable 0 0 0
aCompared with dysplasia, bCompared with Tis, cCompared with T1.
＊Relationship between detection and macroscopic appearance. ND：not 
determined. 
Figure 1　 Macroscopic appearance of UC-associated neoplastic lesions. A. UC-associated 
carcinoma （flat-type）. The height of lesion is almost same as that of adjacent 
non-neoplastic colonic mucosa. B. Dysplastic lesion （UC-III；flat-type）. The 
lesion appears slightly reddish but difficult to discriminate from adjacent non-
neoplastic colonic mucosa. C and D. UC-associated carcinoma （protruding 
type）. The lesions are apparently protruding and possible to discriminate 
from adjacent non-neoplastic colonic mucosa.
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pression was 0％ in UC-II, 52.5％ in UC-III, and 70.4
％ in UC-IV, respectively （Table 2）. Although statisti­
cal analysis showed no difference in the positivity of 
p53 overexpression between UC-III and -IV, UC-II le­
sions had lower positivity of p53 overexpression than 
UC-III （P＝0.027） or -IV lesions （P＝0.003）.
DISCUSSION
A surveillance colonoscopy has been recommended 
for patients with long-standing UC to detect their neo­
plastic lesions at early stage 3〜5）. However, the current 
surveillance still remains unsatisfactory because UC-
associated neoplasia is often difficult to detect endo­
scopically. As shown in Table 1, advanced colitic can­
cer is usually detectable because great morphological 
change can be observed in endoscopic examination. 
However, as we have shown in the present study, the 
detection rate of early colitic cancer and precancerous 
dysplasia is largely decreased compared with that of 
advanced colitic cancer. Although we have no exact 
answers, the difference of macroscopic finding may af­
fect the detection rate of lesions. Thus, most of early 
colitic cancer and dysplasia are of flat-type, and such 
lesions are significantly difficult to detect before sur­
gery when compared with protruding type ones. In 
this regard, Kiesslich et al. have suggested that magni­
fying endoscopy makes it possible to observe the sur­
face （known as the “pit pattern”） of UC-associated 
neoplastic lesions more precisely, resulting in early de­
tection of dysplasia or early colitic cancer at about 90
％ in sensitivity 8）. However, the observation of “pit 
pattern” by magnifying endoscopy has been suggested 
to yield false-positive to diagnose of UC-associated 
neoplastic lesions 9）. Thus, the current surveillance 
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Table 2　Relationship between p53 overexpression and histological diagnosis
Total number of 
lesions
Number of  
positive lesion （％）
P value
Inflammatory change （UC-I） 0 0 （0） ND
Indifinite （UC-II） 5 0 （0）
Neoplastic but not carcinoma （UC-III） 40 21 （52.5） ＜0.05a
Carcinoma （UC-IV） 27 19 （70.4）
＜0.005a
　0.144b
aCompared with UC-II, bCompared with UC-III. ND：not determined. 
Figure 2　 Histology of non-neoplastic epithelium and neoplastic lesions in UC tissues. A-D. Haematoxylin-eosin 
staining. E-H. Immunostaining of p53. p53 immunoreactiviy was hardly observed in the inflammed 
epithelium in lesions classif ied into UC-I （E） and UC-II （F）. Nuclear accumulation of p53 
immmunoreactivity was observed in the dysplastic cells and cancerous cells in lesions classified into UC-III 
（G） and UC-IV （H）. Magnification, （A, B, E, and F） 100×； （C and G） 200×；（D and H） 300×.
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colonoscopy for UC-associated neoplastic lesions still 
needs further improvement.
From the view point of pathology, UC-associated 
neoplasia is also difficult to discriminate from inflam­
matory regenerating epithelium, and therefore, a use­
ful marker to discriminate them would be advanta­
geous to accurate diagnosis of UC-associated neoplasia. 
Of note, several studies have shown that p53 altera­
tions are very frequent in UC-associated neoplasia 
and moreover suggested that p53 alterations is an ear­
ly event in the development of UC-associated neopla­
sia 10〜13）. Then, we have investigated whether p53 
overexpression is useful to discriminate UC-associated 
neoplasia from inflammatory regenerating epithelium 
in the colorectum. Interestingly, we found in the pres­
ent study that p53 overexpression is observed in the 
lesion classified in UC-III and -IV but not in UC-I and 
-II, suggesting that p53 overexpression is observed in 
neoplastic lesions but not in inflammatory regenerating 
epithelium. In this context, immunohistochemistry of 
p53 would be a useful marker of UC-associated neopla­
sia in cases where it is hard to discriminate between 
neoplasia and regenerative epithelium. On the other 
hand, it is known that negative staining for p53 protein 
does not always indicate normality of p53 gene 9）. In­
deed, genetic analysis such as PCR-SSCP is supposed 
to be more accurate than immunohistochemistry to 
discriminate between UC-associated neoplasia and re­
generative epithelium 9）. However, it appears difficult 
in practice to apply such genetic analyses in the patho­
logical diagnosis of UC tissues, whereas it is easier to 
apply immunohistochemistry. Accordingly, we consider 
that immunohistochemistry for p53 is more suitable 
than genetic analyses for the routine diagnosis of UC 
tissues.
In conclusion, UC-associated neoplasia, especially 
precancerous dysplasia and early colitic cancer are dif­
ficult not only to detect by endoscopic ecxamination 
but also to discriminate from inflammed regenerating 
epithelium. In this regard, immunohistochemical analy­
sis of p53 protein is useful to diagnose UC tissues 
pathologically.
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